New antibody TST001 takes on stomach and pancreatic cancers

NCT ID NCT04396821

Ongoing Disease control Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests an experimental drug called TST001, an antibody that targets a protein (Claudin 18.2) found on some cancer cells. It is being studied alone or combined with other treatments like nivolumab or chemotherapy in 150 people with advanced stomach, gastroesophageal junction, or pancreatic cancers. The main goals are to check safety, find the best dose, and see how the body handles the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TST001 (an experimental antibody targeting Claudin 18.2 on cancer cells)
What this could lead to: If successful, this could lead to a new treatment option for advanced stomach, pancreatic, and other solid tumors that have stopped responding to standard therapies.
What could go wrong: This is an early-phase trial focused on safety and dosing, so it is not yet known if TST001 will shrink tumors or improve survival. Side effects from the drug or combinations are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma malignant pancreatic neoplasm neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER GASTRIC CANCER GASTROESOPHAGEAL JUNCTION CANCER PANCREATIC CANCER

Contacts and locations

Locations

Allegheny Hospital

Pittsburgh, Pennsylvania, 15212, United States
Banner MD Anderson

Gilbert, Arizona, 85234, United States
Emory University

Atlanta, Georgia, 30033, United States
Florida Cancer Specialists

Sarasota, Florida, 34232, United States
Gabrail Cancer Research

Canton, Ohio, 44718, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Memorial Sloan Kettering

New York, New York, 10065, United States
NEXT Oncology

Austin, Texas, 78704, United States
Pennsylvania Cancer Specialist Research Institute

Gettysburg, Pennsylvania, 17325, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Stony Brook Cancer Center

Stony Brook, New York, 11794, United States
Swedish Cancer Institute

Seattle, Washington, 98104, United States
University of Arizona

Tucson, Arizona, 85724, United States
University of Kansas, School of Medicine

Kansas City, Kansas, 66160, United States
Vanderbilt University

Nashville, Tennessee, 37232, United States
Wake Forest Baptist Comprehensive Cancer Center

Winston-Salem, North Carolina, 27157, United States
Washington University

St Louis, Missouri, 63110, United States
Yale University

New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.